Nuclear Medicine/Radiopharmaceuticals to Reach $7.27 Billion by 2021 - Increasing Number of Radioisotope Approvals - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Market - Global Forecasts to 2021" report to their offering.

Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The market is in its growth phase with an increasing number of radioisotope approvals for different clinical indications. Ra-223, I-131, and Y-90 ensured their leading position in the nuclear medicine therapeutic market.

Factors such as advances in radiotracers and increasing incidence and prevalence of cancer and cardiac ailments, introduction of alpha emitters for targeted cancer therapy, high demand for radiopharmaceuticals in emerging markets, upcoming radioisotopes, and increasing new product launches by industry players are expected to drive the nuclear medicine/radiopharmaceuticals market in the coming years. However, the shutdown of major nuclear reactors, which are the main source for radiopharmaceutical production, is a major challenge for the growth of the market.

In 2016, North America is expected to account for the largest share of the global nuclear medicine/radiopharmaceuticals market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate in the forecast period. Factors such as the increasing geriatric population and incidence of cardiovascular diseases & cancer in China & Japan, installation of PET scanners in India, and approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) in Australia are likely to propel the market in the Asia-Pacific region.

Companies Mentioned:

  • Advanced Accelerator Applications S.A.
  • Bayer AG
  • Bracco Imaging S.P.A
  • Cardinal Health, Inc.
  • Eczacibasi-Monrol Nuclear Products
  • GE Healthcare
  • IBA Molecular
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt PLC
  • Nordion, Inc.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Nuclear Medicine Market, By Type

7 Nuclear Medicine Market, By Application

8 Nuclear Medicine Market, By Procedural Volume

9 Global Nuclear Medicine Market, By Region

10 Global Nuclear Medicine Market, By Region

11 Competitive Landscape

12 Company Profiles

13 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/jjj865/nuclear

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Nuclear Medicine and Radiopharmacology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Nuclear Medicine and Radiopharmacology